- In January 2025, Medtronic, a global leader in medical technology, announced the successful completion of its first human trial for pulsed field ablation (PFA) devices, showcasing a breakthrough in cardiac arrhythmia treatment. This development is expected to pave the way for enhanced patient safety and more efficient treatments for atrial fibrillation, with minimal tissue damage compared to traditional methods
- In December 2024, Boston Scientific Corporation presented new clinical trial data at the Heart Rhythm Society 2024 meeting. The data demonstrated the superiority of PFA devices in reducing procedure times and improving patient outcomes for atrial fibrillation treatments. The company also highlighted its upcoming plans to expand its portfolio of PFA devices, focusing on innovations that ensure faster and more precise ablation procedures
- In November 2024, Abbott Laboratories launched an upgraded version of its PFA catheter, featuring enhanced design and precision ablation capabilities. This new catheter technology offers greater tissue contact and improved mapping features, contributing to faster recovery times for patients undergoing atrial fibrillation procedures
- In October 2024, Biotronik unveiled its latest pulsed field ablation generator at the European Heart Rhythm Association (EHRA) conference. The device incorporates advanced energy delivery systems that reduce the risk of collateral damage and improve the efficacy of cardiac ablation procedures, leading to better clinical outcomes in patients with complex arrhythmias
- In September 2024, Johnson & Johnson’s subsidiary, Biosense Webster, received FDA approval for its next-generation PFA system. This system promises to provide higher precision, shorter procedure durations, and improved patient safety profiles for those undergoing ablation treatments for atrial fibrillation. The company is now planning for global expansion of its PFA devices, with focus on training healthcare professionals and improving treatment protocols
